Pfizer to Seek Successor as Chief Science Officer Mikael Dolsten Steps Down

Pfizer to Seek Successor as Chief Science Officer Mikael Dolsten Steps Down

Pfizer Inc. has announced that Chief Scientific Officer and President of Worldwide Research & Development, Dr. Mikael Dolsten, will be stepping down after a tenure of over 15 years. Dolsten, who played a significant role in the development of Pfizer's COVID-19 vaccine, joined the company through the acquisition of Wyeth in 2009. He will continue in his current role until a successor is identified and a transition is complete.

The company has initiated the process to find Dolsten's successor, which is expected to last several months and may extend into early next year. Pfizer plans to conduct an external search for the new Chief Scientific Officer. During his time at Pfizer, Dolsten has overseen the approval of more than 35 drugs and vaccines, including new molecular entities. The company acknowledges that the future holds various risks and uncertainties related to its research and development pipeline.

Summary

Other news in science